Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Xenetic Biosciences Acquires Rights to Virexxa from Kevelt 11
Partnerships 12
Xenetic Biosciences Enters into Agreement with Excivion 12
Lipoxen Enters Into Co-Development Agreement With SynBio 13
Lipoxen Extends Co-Development Agreement With IAVI 14
Licensing Agreements 15
Baxalta Enters into Licensing Agreement with Xenetic Biosciences 15
Serum Institute of India Enters into Licensing Agreement with Xenetic Biosciences 16
Equity Offering 17
Xenetic Biosciences Raises USD10 Million in Public Offering of Units 17
Lipoxen Completes Private Placement Of Shares For US$19.91 Million 19
Debt Offering 21
Xenetic Biosciences Raises USD3 Million in Private Placement of 10% Notes 21
Acquisition 22
OPKO Health Acquires 6.3% Interest in Xenetic Biosciences 22
General Sales Completes Reverse Acquisition Transaction with Xenetic Biosciences 23
Xenetic Biosciences Completes Acquisition Of SymbioTec For US$14.4 Million 24
Xenetic Biosciences Inc – Key Competitors 25
Xenetic Biosciences Inc – Key Employees 26
Xenetic Biosciences Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Nov 15, 2017: Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update 28
Aug 15, 2017: Xenetic Biosciences Reports 2017 Second Quarter Financial Results and Provides Business Update 30
May 16, 2017: Xenetic Biosciences Reports 2017 First Quarter Financial Results and Provides Business Update 32
Apr 03, 2017: Xenetic Biosciences Reports 2016 Year End Financial Results and Provides Business Update 33
Nov 15, 2016: Xenetic Biosciences Reports Third Quarter Financial Results and Provides Business Update 35
Corporate Communications 37
Oct 31, 2017: Xenetic Biosciences Appoints Jeffrey F. Eisenberg as Chief Executive Officer 37
Aug 14, 2017: Xenetic Biosciences Announces Appointment of Three Directors to the Board 38
Apr 04, 2017: Xenetic Biosciences Expands Executive Management Team with Appointment of James F. Parslow, MBA, CPA as Chief Financial Officer 39
Jan 04, 2017: Xenetic Biosciences Appoints Curtis A. Lockshin, Ph.D. as Chief Scientific Officer 40
Dec 06, 2016: Xenetic Biosciences Expands Management Team with Key Appointment of Jeffrey F. Eisenberg as Chief Operating Officer 41
Dec 05, 2016: Xenetic Biosciences appoints new COO 42
Nov 22, 2016: Xenetic Biosciences appoints new board member 43
Nov 22, 2016: Xenetic Biosciences Appoints Edward J. Benz, Jr., M.D., Former Dana-Farber CEO, to its Board of Directors 44
Jul 11, 2016: Xenetic Biosciences Appoints Jeffrey F. Eisenberg to the Board of Directors 45
Feb 29, 2016: Xenetic Biosciences Appoints Renowned Chemist and Nobel Laureate, Dr. Roger D. Kornberg, to Board of Directors 46
Product News 47
Dec 01, 2016: Xenetic Biosciences to Present at the LD Micro 2016 Annual Conference 47
Sep 22, 2016: Xenetic Biosciences to Present at the Ladenburg Thalmann 2016 Healthcare Conference 48
Apr 20, 2017: Xenetic Biosciences’ PolyXen Platform Technology Accepted for Poster Presentation at the 13th Annual Protein Engineering Summit (PEGS) Boston 49
Clinical Trials 50
Oct 10, 2016: Xenetic Biosciences Reports Positive Topline Data from Third Cohort of Phase 2 Dose-Escalation Trial of ErepoXen for Anemia 50
Apr 01, 2016: PJSC Pharmsynthez Completes Follow Up and Data Analysis From a Phase 2 Study of Novel Therapeutic Vaccine Xemys for Multiple Sclerosis 51
Other Significant Developments 52
Mar 27, 2017: Xenetic Biosciences Provides Update on Patent Portfolio Development 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Xenetic Biosciences Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Xenetic Biosciences Acquires Rights to Virexxa from Kevelt 11
Xenetic Biosciences Enters into Agreement with Excivion 12
Lipoxen Enters Into Co-Development Agreement With SynBio 13
Lipoxen Extends Co-Development Agreement With IAVI 14
Baxalta Enters into Licensing Agreement with Xenetic Biosciences 15
Serum Institute of India Enters into Licensing Agreement with Xenetic Biosciences 16
Xenetic Biosciences Raises USD10 Million in Public Offering of Units 17
Lipoxen Completes Private Placement Of Shares For US$19.91 Million 19
Xenetic Biosciences Raises USD3 Million in Private Placement of 10% Notes 21
OPKO Health Acquires 6.3% Interest in Xenetic Biosciences 22
General Sales Completes Reverse Acquisition Transaction with Xenetic Biosciences 23
Xenetic Biosciences Completes Acquisition Of SymbioTec For US$14.4 Million 24
Xenetic Biosciences Inc, Key Competitors 25
Xenetic Biosciences Inc, Key Employees 26
Xenetic Biosciences Inc, Subsidiaries 27